Dispatches from BPI Europe 2016

Looking to make third wave biosimilars? MOA crucial for cell line development, Formycon

By Dan Stanton contact

- Last updated on GMT

iStock/Thurston Photo
iStock/Thurston Photo

Related tags: Monoclonal antibodies

Fully understanding a molecule’s mode-of-action (MOA) will be essential as industry begins developing the third generation of biosimilar products, according to Formycon.

“Biosimilars is one of the hottest topics in the bioprocess industry today and is too large a sector to be ignored,”​ Carsten Brockmeyer, CEO of Formycon told delegates this week at the Bioprocess International European Summit in Vienna, Austria.

His company is developing a range of biosimilars, but unlike the vast majority of the estimated 250 and growing​ developers of such products, Formycon is concentrating on "third wave" products.

First wave biosimilars are those copies of biological products already off patent, and are generally cytokines, growth factors and hormones such as filgrastim and epoetin alfa – copies of Amgen’s Neupogen and Epogen, respectively. Second wave biosimilars are generally monoclonal antibodies which come off patent before 2020, Pfizer/Celltrion’s recently US approved infliximab​ being an example.

Third wave biosimilars, according to Brockmeyer, are those biological products coming off patent after 2020 and generally more complex mAbs or antibody fragments. Formycon has three such products in its pipeline: versions of Genentech’s Lucentis (ranibizumab), Regeneron’s Eylea (aflibercept), and a third undisclosed molecule.

But to join the handful of developers delving into this distant market opportunity, Brockmeyer said “a full understanding of the mode-of-action for the biosimilar targets will be critical in picking the right cell lines and reverse engineer the upstream and downstream processes.”

Lucentis uses E. Coli as its host cell line, while Eylea uses Chinese Hamster Ovary (CHO) cells. Other examples of such products include Biogen’s Tysabri (natalizumab) and Janssen’s Stelera (ustekinumab), which use the mouse myeloma-derived NS0 and SP2/0 host cell lines, respectively.

Understanding the mode-of-action for these cell lines is essential for criticality assessment, he added, which would help fulfil the regulatory demands for evaluating quality attributes and equivalence through the US FDA’s three-tier assessment approach​, which he said is yet to be fully understood by industry.

Related news

Show more

Related products

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Discover the world of upstream bioprocessing

Discover the world of upstream bioprocessing

Eppendorf Bioprocess Solutions | 07-Sep-2022 | Technical / White Paper

A must-read for all bioprocess scientists: This bundle of four ebooks created by Eppendorf guides you through the world of upstream bioprocessing.

Follow us


View more